News

Gisborne Hospital Permanent, full-time role A rare opportunity to lead and shape a high-impact outpatient service, drive innovative models of care, and make a meaningful difference for the Tairāwhiti community while enjoying the lifestyle benefits of living in Gisborne Health New Zealand | Te Whatu Ora is firmly grounded in the principles of Te Tiriti o Waitangi and is committed to building a health system that serves all New Zealanders. About the role We are looking for an experienced and...

Just over 3 weeks to go!  Goodfellow Symposium 2026 In the meantime, here are our latest webinars and podcasts:  Sexuality & Intimacy Workshop FACE-TO-FACE WORKSHOP in AUCKLAND 26 & 27 February: Join Allyson Waite for a 2-day workshop designed to extend your knowledge regarding sexuality and intimacy.   Register here   Whole of life protection: A focus on adult vaccination WEBINAR 3 March: Nikki Turner on the importance of adult immunisation as part of comprehensive preventive care in...

Pharmac is seeking feedback on a proposal to widen access to nivolumab and ipilimumab for people with stage 3B to stage 4 melanoma that can be removed with surgery. If approved, funded access to these medicines would be widened from 1 May 2026. For more information on this consultation, read the full proposal to widen access to nivolumab and ipilimumab for resectable melanoma We welcome your feedback. Consultation is open until 5pm Monday 9 March 2026. Please send your feedback to...

We are writing to inform you that from 1 March 2026, the following treatments will be available in the community via listing in Section B of the Pharmaceutical schedule:   For Primary Response in Medical Emergencies PRIME services Droperidol inj 2.5 mg per ml (1 ml ampoule) Glucose inj 5% (100 ml bag) Glucose inj 10% (500 ml bag) Ketamine inj 100 mg per ml (2 ml vial) Methoxyflurane solution for inhalation 999 mg per g (3 ml bottle and plastic inhaler, and 3 ml bottles) Tranexamic acid inj...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 20 February 2026. It includes information on:  New updates Resolved Supply Issues Improving access to treatments in the community for trauma and medical emergencies, and ketamine for palliative care From 1 March 2026, the following treatments will be available and funded on the Community Schedule: For Primary Response in Medical Emergencies PRIME services Droperidol...

New medicine supply notices Chloramphenicol (Devatis) Eye ointment 1% (Pharmacode: 2576902) Supplies of this product are low due to a shortage of the active ingredient. The eye drops are available as an alternative.  Dexamethasone phosphate (Medsurge) Inj 4 mg per ml, 2 ml ampoule  (Pharmacode: 2690535) The supplier has limited stock of the 2 ml ampoule. There is stock of the 1 ml ampoule. Olanzapine (Zypine ODT) 10 mg orodispersible tablets (Pharmacode: 2439840) Due to manufacturing and...